Results and Discussion:
Between weeks 28 and 30 after the start ofradiation therapy, among evaluable participants, 79 percent who received tadalafil retained erectile function compared with 74 percent who received placebo, an absolute difference of 5percent. A significant difference between groups was also not observed at 1 year (72 percent vs 71percent). Tadalafil was not associated with improved overall sexual function or satisfaction, and partners of men assigned tadalafil noted no significant effect on sexual satisfaction.